View in EDS

The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.

Saved in:
Bibliographic Details
Title: The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.
Authors: O'Donnell P; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA. patricio.odonnell@sagerx.com.; McLean Hospital, Department of Psychiatry, Harvard Medical School, Boston, MA, USA. patricio.odonnell@sagerx.com., Dong C; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA., Murthy V; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA., Asgharnejad M; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA., Du X; Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA., Summerfelt A; Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA., Lu H; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA., Xu L; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA., Wendland JR; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA., Dunayevich E; Neurocrine Biosciences, Inc., San Diego, CA, USA., Buhl DL; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA., Litman R; CBH Health, Gaithersburg, MD, USA., Hetrick WP; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA., Hong LE; Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA., Rosen LB; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.
Source: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2023 Jun; Vol. 48 (7), pp. 1052-1059. Date of Electronic Publication: 2023 Mar 16.
Publication Type: Randomized Controlled Trial; Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8904907 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1740-634X (Electronic) Linking ISSN: 0893133X NLM ISO Abbreviation: Neuropsychopharmacology Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36928351
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22O'Donnell+P%22">O'Donnell P</searchLink>; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA. patricio.odonnell@sagerx.com.; McLean Hospital, Department of Psychiatry, Harvard Medical School, Boston, MA, USA. patricio.odonnell@sagerx.com.<br /><searchLink fieldCode="AU" term="%22Dong+C%22">Dong C</searchLink>; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Murthy+V%22">Murthy V</searchLink>; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Asgharnejad+M%22">Asgharnejad M</searchLink>; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Du+X%22">Du X</searchLink>; Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Summerfelt+A%22">Summerfelt A</searchLink>; Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Lu+H%22">Lu H</searchLink>; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Xu+L%22">Xu L</searchLink>; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Wendland+JR%22">Wendland JR</searchLink>; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Dunayevich+E%22">Dunayevich E</searchLink>; Neurocrine Biosciences, Inc., San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Buhl+DL%22">Buhl DL</searchLink>; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Litman+R%22">Litman R</searchLink>; CBH Health, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Hetrick+WP%22">Hetrick WP</searchLink>; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.<br /><searchLink fieldCode="AU" term="%22Hong+LE%22">Hong LE</searchLink>; Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Rosen+LB%22">Rosen LB</searchLink>; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228904907%22">Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</searchLink> [Neuropsychopharmacology] 2023 Jun; Vol. 48 (7), pp. 1052-1059. <i>Date of Electronic Publication: </i>2023 Mar 16.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8904907 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1740-634X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220893133X%22">0893133X </searchLink><i>NLM ISO Abbreviation: </i>Neuropsychopharmacology <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36928351
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41386-023-01560-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1052
    Titles:
      – TitleFull: The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: O'Donnell P
      – PersonEntity:
          Name:
            NameFull: Dong C
      – PersonEntity:
          Name:
            NameFull: Murthy V
      – PersonEntity:
          Name:
            NameFull: Asgharnejad M
      – PersonEntity:
          Name:
            NameFull: Du X
      – PersonEntity:
          Name:
            NameFull: Summerfelt A
      – PersonEntity:
          Name:
            NameFull: Lu H
      – PersonEntity:
          Name:
            NameFull: Xu L
      – PersonEntity:
          Name:
            NameFull: Wendland JR
      – PersonEntity:
          Name:
            NameFull: Dunayevich E
      – PersonEntity:
          Name:
            NameFull: Buhl DL
      – PersonEntity:
          Name:
            NameFull: Litman R
      – PersonEntity:
          Name:
            NameFull: Hetrick WP
      – PersonEntity:
          Name:
            NameFull: Hong LE
      – PersonEntity:
          Name:
            NameFull: Rosen LB
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2023 Jun
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1740-634X
          Numbering:
            – Type: volume
              Value: 48
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
              Type: main
ResultId 1